A "sub-study" of a late-stage clinical trial found the drug, obicetrapib, significantly reduced levels of a certain type of tau protein linked to Alzheimer's development.
A "sub-study" of a late-stage clinical trial found the drug, obicetrapib, significantly reduced levels of a certain type of tau protein linked to Alzheimer's development.
